National Institute on Drug Abuse; Notice of Closed Meetings, 29128-29129 [2018-13418]
Download as PDF
<![CDATA[
29128
Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Recombinant HIV-1 Envelope Protein
for Vaccine Use
Description of Technology
In pursuit of an effective vaccine to
end the global HIV-1/AIDS pandemic,
researchers at the Vaccine Research
Center (‘‘VRC’’) continue to study the
structure of HIV-1. Recently, these
researchers have determined the threedimensional structure of the HIV-1
Envelope trimeric ectodomain (‘‘Env’’),
comprised of three gp120 and three
gp41 subunits, in its prefusion, mature,
closed conformation.
The researchers hypothesize that
immunization with the prefusion,
closed HIV-1 Env protein will elicit a
neutralizing immune response. The VRC
researchers engineered a portion of the
HIV-1 Env trimer to stabilize it in this
closed conformation for use as an
immunogen.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
trimeric pre-fusion HIV-1 Env. Nature.
2014 Oct 23; 514(7523):455–61. [PMID:
25296255].
Intellectual Property: HHS Reference
Number E–178–2014 includes U.S.
Provisional Patent Application No. 62/
046,059 filed September 4, 2014; U.S.
Provisional Patent Application No. 62/
136,480 filed March 21, 2015; PCT
Application No. PCT/US2015/048729
filed September 4, 2015; U.S. Patent
Application No. 15/508,885 filed March
3, 2017; and EPO Patent Application
No. 15766697.5 filed March 29, 2017.
Licensing Contact: Dr. Barry
Buchbinder, 240–627–3674;
barry.buchbinder@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize HIV-1 immunogens for
treating or preventing HIV-1 infection.
For collaboration opportunities, please
contact Dr. Barry Buchbinder, 240–627–
3674; barry.buchbinder@nih.gov.
Dated: June 14, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–13416 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
Potential Commercial Applications
• Vaccine for prevention of HIV-1
infection.
• Therapeutic vaccine for treatment
of HIV-1 infection.
Competitive Advantages
daltland on DSKBBV9HB2PROD with NOTICES
Development Stage
• In vitro studies characterizing the
immunogen and its interaction with HIV
antibodies.
• In vivo results including
immunogenicity in rabbits and guinea
pigs, neutralizing activity of resulting
serum.
Inventors: Peter D. Kwong (NIAID),
Ivelin S. Georgiev (NIAID), Michael
Gordon Joyce (NIAID), Marie L. Pancera
(NIAID), Tongqing Zhou (NIAID),
Priyamvada Acharya (NIAID), Jason J.
Gorman (NIAID), Yongping Yang
(NIAID), Aliaksandr A. Druz (NIAID),
Guillaume Stewart-Jones (NIAID), Rita
Chen (NIAID), Gwo-Yu Chuang (NIAID),
Ulrich Baxa (NIAID), John R. Mascola
(NIAID), Rebecca M. Lynch (NIAID),
Baoshan Zhang (NIAID), Cheng Cheng
(NIAID).
Publications: Pancera M., et al.
Structure and immune recognition of
17:16 Jun 21, 2018
Jkt 244001
National Institutes of Health
National Eye Institute; Notice of Closed
Meetings
• Currently, no licensed HIV-1
vaccine exists.
VerDate Sep<11>2014
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Cooperative
Agreement (UG1) and Clinical Trial Planning
Grant (R34) Applications.
Date: July 13, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Place: National Institutes of Health, 5635
Fishers Lane, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Anne E. Schaffner, Ph.D.,
Chief, Scientific Review Branch, Division of
Extramural Research, National Eye Institute,
5635 Fishers Lane, Suite 1300, MSC 9300,
Bethesda, MD 20892–9300, (301) 451–2020,
aes@nei.nih.gov.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Research
Project Grant Applications (R01).
Date: July 25, 2018.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health 5635
Fishers Lane, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Brian Hoshaw, Ph.D.,
Scientific Review Officer National Eye
Institute National Institutes of Health,
Division of Extramural Research 5635 Fishers
Lane, Suite 1300, Rockville, MD 20892, 301–
451–2020, hoshawb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13413 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Receptor Profiling and Predictive Toxicology
(8937).
Date: July 19, 2018.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
E:\FR\FM\22JNN1.SGM
22JNN1
Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 827–5702, lf33c.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Synthetic Peptides and Other Drugs of
Abuse—Purity Determination, Stability
Testing, & Quantitative Analysis (8945).
Date: August 7, 2018.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 827–5702, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13418 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
daltland on DSKBBV9HB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Biophysical, Physiological,
Pharmacological and Bioengineering
Neuroscience.
Date: June 28, 2018.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
17:16 Jun 21, 2018
Jkt 244001
Place: Embassy Suites DC Convention
Center, 900 10th Street NW, Washington, DC
20001.
Contact Person: Sussan Paydar, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, RM 5222,
Bethesda, MD 20817, (301) 827–4994,
sussan.paydar@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 18, 2018.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13389 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neurodevelopmental Disorders.
Date: June 27, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Pat Manos, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5200,
MSC 7846, Bethesda, MD 20892, 301–408–
9866, manospa@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
29129
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Motivated Behavior.
Date: July 11–12, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Michael Selmanoff, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5164,
MSC 7844, Bethesda, MD 20892, 301–435–
1119, selmanom@csr.nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group; HIV/
AIDS Vaccines Study Section.
Date: July 13, 2018.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW,
Washington, DC 20015.
Contact Person: Barna Dey, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–435–0000, bdey@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Molecular Mechanisms of
Alzheimer’s Disease, Synaptic Function, and
Neurodevelopment.
Date: July 17, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Carol Hamelink, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4192,
MSC 7850, Bethesda, MD 20892, (301) 213–
9887, hamelinc@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–17–
340: Collaborative Program Grant for
Multidisciplinary Teams (RM1).
Date: July 17, 2018.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Thomas Beres, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5148,
MSC 7840, Bethesda, MD 20892, 301–435–
1175, berestm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 83, Number 121 (Friday, June 22, 2018)]
[Notices]
[Pages 29128-29129]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13418]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Receptor Profiling and Predictive Toxicology (8937).
Date: July 19, 2018.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
[[Page 29129]]
Contact Person: Lyle Furr, Scientific Review Officer, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 827-5702, lf33c.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Synthetic Peptides and Other Drugs of Abuse--Purity
Determination, Stability Testing, & Quantitative Analysis (8945).
Date: August 7, 2018.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Lyle Furr, Scientific Review Officer, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 827-5702, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance Program No.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-13418 Filed 6-21-18; 8:45 am]
BILLING CODE 4140-01-P
